MX2011010324A - Tableta recubierta que se desintegra oralmente. - Google Patents

Tableta recubierta que se desintegra oralmente.

Info

Publication number
MX2011010324A
MX2011010324A MX2011010324A MX2011010324A MX2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A MX 2011010324 A MX2011010324 A MX 2011010324A
Authority
MX
Mexico
Prior art keywords
orally disintegrating
coated tablet
coating layer
disintegrating coated
medicament
Prior art date
Application number
MX2011010324A
Other languages
English (en)
Inventor
Kotoe Ohta
Suguru Takaki
Yasuhide Horiuchi
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2011010324A publication Critical patent/MX2011010324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una tableta recubierta estable que se desintegra oralmente conteniendo un fármaco en donde la tableta se recubre con una capa de recubrimiento conteniendo una sustancia soluble en agua y una resina de poli (alcohol vinilico ) de no menos de 5% por peso con base en el peso de la capa de recubrimiento, la sustancia soluble en agua disolviéndose en una cantidad de 1g o mas en menos de 10 ml de agua a 20° C, teniendo grupos hidroxilo en su molécula, y teniendo un peso molecular de no más de 200 por unidad de grupo hidroxilo. Se proporciona una tableta recubierta estable que se desintegra oralmente que no ocasiona una fractura en la capa de recubrimiento aun cuando la tableta que se desintegra oralmente ha sido hinchada por absorción de humedad bajo alta humedad, mientras que asegura propiedades de rápida desintegración en una cavidad oral. En el caso de una tableta que se desintegra oralmente conteniendo un fármaco inestable a al a luz, degradación del fármaco puede suprimirse mediante mezclar físicamente un agente que obscurece la luz en la capa de recubrimiento. Superficie.
MX2011010324A 2009-03-30 2010-03-29 Tableta recubierta que se desintegra oralmente. MX2011010324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009081916 2009-03-30
PCT/JP2010/055517 WO2010113841A1 (ja) 2009-03-30 2010-03-29 口腔内崩壊性被覆錠剤

Publications (1)

Publication Number Publication Date
MX2011010324A true MX2011010324A (es) 2011-12-16

Family

ID=42828131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010324A MX2011010324A (es) 2009-03-30 2010-03-29 Tableta recubierta que se desintegra oralmente.

Country Status (15)

Country Link
US (1) US8715730B2 (es)
EP (1) EP2415466B1 (es)
JP (2) JP5549586B2 (es)
KR (1) KR101682965B1 (es)
CN (1) CN102448445B (es)
AU (1) AU2010231701B2 (es)
BR (1) BRPI1014085B1 (es)
CA (1) CA2756877C (es)
ES (1) ES2572761T3 (es)
HU (1) HUE028195T2 (es)
MX (1) MX2011010324A (es)
PL (1) PL2415466T3 (es)
PT (1) PT2415466T (es)
TW (1) TWI455733B (es)
WO (1) WO2010113841A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344533A (zh) * 2009-01-29 2017-01-25 大日本住友制药株式会社 具有内核的口腔崩解片剂
JP5782312B2 (ja) * 2011-07-01 2015-09-24 日新化成株式会社 コーティング用組成物
JP5916091B2 (ja) * 2012-01-31 2016-05-11 大原薬品工業株式会社 口腔内崩壊錠のｕｖレーザー印刷方法
JP2015514715A (ja) * 2012-03-30 2015-05-21 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド コルヒチン製剤、その製造方法および使用方法
JP6363993B2 (ja) * 2012-04-27 2018-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ コーティングを有する錠剤および該錠剤の製造
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
JP6107226B2 (ja) * 2013-02-26 2017-04-05 ニプロ株式会社 医薬組成物
WO2014157264A1 (ja) * 2013-03-27 2014-10-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 口腔内崩壊性フィルムコーティング錠
JP6182744B2 (ja) * 2013-03-29 2017-08-23 三笠製薬株式会社 ナルフラフィン含有経皮吸収貼付剤
EP3106152B1 (en) * 2014-02-12 2021-02-17 Sawai Pharmaceutical Co., Ltd. Orally disintegrating tablet coated with film
TWI658842B (zh) 2014-03-31 2019-05-11 日商東麗股份有限公司 固體製劑用之被覆劑以及由其所形成之被膜及被覆固體製劑
CN104473882B (zh) * 2014-12-25 2018-10-02 北京华禧联合科技发展有限公司 一种甲钴胺颗粒
ES2951884T3 (es) 2015-01-01 2023-10-25 Ideal Cures Pvt Ltd Novedosa composición de recubrimiento de película
EP3281625B1 (en) * 2015-04-07 2020-02-26 Nipro Corporation Oral film preparation
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI740994B (zh) * 2016-07-29 2021-10-01 日商東麗股份有限公司 經光穩定性提升之固體製劑
CN107865827B (zh) * 2016-09-28 2022-04-05 四川海思科制药有限公司 一种聚普瑞锌口腔崩解片药物组合物及其制备方法
CN110314149B (zh) * 2016-10-17 2021-04-02 吉林省博大伟业制药有限公司 一种聚普瑞锌片及其制备工艺
US11071734B2 (en) 2017-03-31 2021-07-27 Toray Industries, Inc. Tableted medicinal composition comprising nalfurafine
US11013702B2 (en) 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
AU2019229892A1 (en) 2018-03-08 2020-09-03 University Of Kansas Treatment of demyelinating diseases
KR102120720B1 (ko) * 2018-07-16 2020-06-10 연성정밀화학(주) 날푸라핀 함유 구강붕해정
EP3846792A4 (en) 2018-09-06 2022-10-12 Innopharmascreen Inc. METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE
MX2018011699A (es) 2018-09-26 2019-07-24 Federico Amezcua Amezcua Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
JP7219979B2 (ja) * 2020-02-26 2023-02-09 日新製薬株式会社 被覆層を有する口腔内崩壊錠

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
US6207199B1 (en) 1994-01-27 2001-03-27 The Board Of Regents Of The University Of Oklahoma Process for making a particulate support matrix for making a rapidly dissolving dosage form
BR9506579A (pt) * 1994-01-27 1997-09-16 Univ Oklahoma Matriz de suporte particulado forma de dosagem farmacêutica sólida de rápida dissolução processo para a preparação da matriz de suporte particulado e processo para a preparação da forma de dosagem farmacêutica sólida de rápida dissolução
JP3274573B2 (ja) 1994-08-25 2002-04-15 興和株式会社 フィルムコーティング組成物およびそれを用いた固形製剤
PT948965E (pt) 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
JP4465728B2 (ja) 1998-12-10 2010-05-19 大正製薬株式会社 糖衣錠
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
US6801919B2 (en) 2001-07-27 2004-10-05 Hewlett-Packard Development Company, L.P. Object oriented database interface encapsulation that allows for chronologically overlapping transactions in a multi-threaded environment
DE60308647T2 (de) 2002-02-07 2007-08-09 Pharmacia Corp. Pharmazeutische darreichungsform zur mukosalen verabreichung
GB0204772D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
GB0211620D0 (en) 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
JP2006076971A (ja) * 2004-09-13 2006-03-23 Basf Ag 口腔内崩壊錠
WO2007018192A1 (ja) * 2005-08-10 2007-02-15 Shionogi & Co., Ltd. 口腔内崩壊錠剤
JP4879542B2 (ja) 2005-09-28 2012-02-22 京都薬品工業株式会社 フィルムコーティング錠剤
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
JP2008261849A (ja) 2007-03-20 2008-10-30 Nippon Shinyaku Co Ltd 鎮痒物質のスクリーニング方法及び評価方法
ES2381056T3 (es) 2007-04-26 2012-05-22 Toray Industries, Inc. Preparación sólida estable que contiene un derivado de 4,5-epoximorfinano
CN101707930B (zh) * 2007-06-06 2013-10-30 巴斯夫欧洲公司 用于制备快速崩解的片剂的药物配制剂

Also Published As

Publication number Publication date
TW201038298A (en) 2010-11-01
KR20110135870A (ko) 2011-12-19
AU2010231701B2 (en) 2015-04-09
HUE028195T2 (en) 2016-12-28
PT2415466T (pt) 2016-07-14
CA2756877A1 (en) 2010-10-07
BRPI1014085A2 (pt) 2016-04-19
US8715730B2 (en) 2014-05-06
CN102448445B (zh) 2014-03-05
AU2010231701A1 (en) 2011-11-17
PL2415466T3 (pl) 2016-10-31
EP2415466B1 (en) 2016-05-11
KR101682965B1 (ko) 2016-12-06
EP2415466A1 (en) 2012-02-08
BRPI1014085B1 (pt) 2020-03-10
JP5696742B2 (ja) 2015-04-08
CA2756877C (en) 2016-08-16
JP2013177438A (ja) 2013-09-09
JP5549586B2 (ja) 2014-07-16
CN102448445A (zh) 2012-05-09
EP2415466A4 (en) 2012-08-29
JPWO2010113841A1 (ja) 2012-10-11
WO2010113841A1 (ja) 2010-10-07
US20120058186A1 (en) 2012-03-08
ES2572761T3 (es) 2016-06-02
TWI455733B (zh) 2014-10-11

Similar Documents

Publication Publication Date Title
MX2011010324A (es) Tableta recubierta que se desintegra oralmente.
DE602007010254D1 (de) Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack
NZ600640A (en) Abuse-resistant formulations
PL1933809T3 (pl) Kompozycje do dostarczania donosowego
MX347753B (es) Formulaciones resistentes al abuso.
RS54310B1 (en) AHLIDINIUM INHALATION COMPONENT CONTAINING ACLIDINIUM FOR ASTMA TREATMENT
WO2007095600A3 (en) Disintegrable oral films
EP3895700A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
EP2210591A3 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
NZ608239A (en) Aqueous drug delivery system comprising off - flavor masking agent
MY177027A (en) Novel dosage and formulation
MX2013007237A (es) Peliculas y composiciones que comprenden las mismas.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
MX2012013021A (es) Formulaciones resistentes a alcohol.
MX2012004316A (es) Agente de recubrimiento de pelicula para la preparacion de solidos y preparacion de solidos utilizando el mismo.
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων
TW200744676A (en) Pharmaceutical compositions for the eradication of helicobacter pylori
PL2252263T3 (pl) Postać galenowa do podawania tryptanów poprzez błonę śluzową policzka
UA36877U (ru) Противомикробная стоматологическая пленка для лечения заболеваний полости рта
GR20100100508A (el) Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου
WO2010095158A8 (en) Pharmaceutical composition containing microcolloidal silver and carboxymethyl beta glucan for disinfection of the nasal mucosae, and process for preparation thereof
Makhmalzadeh et al. STUDY OF FREE-FILMS AND COATED TABLETS BASED ON HPMC AND MICROCRYSTALLINE CELLULOSE, AIMED FOR IMPROVE STABILITY OF MOISTURE-SENSITIVE DRUGS
MY141878A (en) Method of enhancing absorptions of transmucosal administration formulations
UA43019U (ru) Средство с хлоргексидином для лечения заболеваний пародонта и слизистой оболочки полости рта